## Gene Summary
LTC4S, or leukotriene C4 synthase, is a crucial enzyme in the leukotriene biosynthesis pathway. This gene encodes for an 18-kDa enzyme that is located predominantly in the nuclear envelope and endoplasmic reticulum. LTC4S catalyzes the conjugation of glutathione to leukotriene A4 (LTA4), a reactive epoxide intermediate, to form leukotriene C4 (LTC4). LTC4S plays a significant role in the inflammatory response, particularly in mediating bronchoconstriction, vasoconstriction, and increased vascular permeability, which are primary features in conditions like asthma and allergic reactions.

## Gene Drugs, Diseases, Phenotypes, and Pathways
LTC4S is pivotal in the biosynthesis of cysteinyl leukotrienes (CysLTs), which are potent mediators in inflammatory diseases, notably asthma, allergic rhinitis, and other allergic conditions. The dysregulation or overexpression of this gene is linked with increased susceptibility to these disorders due to the enhanced production of CysLTs. Known pathways associated with LTC4S primarily revolve around arachidonic acid metabolism and the leukotriene signaling pathway, which are integral in inflammation and hypersensitivity reactions.

## Pharmacogenetics
The pharmacogenetics of LTC4S chiefly concerns its impact on the efficacy and risk of adverse effects of drugs that target leukotriene pathways, such as the leukotriene receptor antagonists (LTRAs) - Montelukast and Zafirlukast - commonly used in managing asthma and allergic rhinitis. Polymorphisms within the LTC4S gene, such as the A-444C variant, have been studied for their association with variation in response to these medications. Individuals carrying specific variants might experience differential therapeutic outcomes or risk profiles when treated with LTRAs, highlighting the importance of considering LTC4S genotypes in personalized medicine approaches for inflammatory and allergic diseases.